CDRH Compliance Office Looks Ahead To 2016
This article was originally published in The Gray Sheet
Executive Summary
More emphasis on informal interactions with companies for minor concerns will be one hallmark of the FDA device center's Office of Compliance agenda for the coming year, according to Acting Director Sean Boyd, who provided an overview of the office's 2016 priorities.
You may also be interested in...
FDA Report: MDSAP Single-Audit Pilot Challenged By Device-Maker Recruitment
A mid-pilot program update from the Medical Device Single Audit Program shows the number of interested manufacturers spiked sharply in July, but is still a far cry from the end-of-2016 target of 330 participating companies. However, the pilot is meeting auditor recruitment and training goals.
Analysis: Foreign Firms Hit With Majority Of FDA Quality-Linked Warning Letters Last Year
Most of the 150 warning letters issued by FDA last year were sent to foreign manufacturers, a “Silver Sheet” analysis shows. That letters to overseas companies have outpaced those to domestic ones is a surprise given that the agency performs nearly four times as many inspections of U.S.-based facilities each year. But the foreign warning letter increase in 2013 might actually be a sign that FDA’s enhanced focus on overseas compliance in recent years has begun paying dividends. In related warning letter trends, CAPA has supplanted complaint handling as the No. 1 deficiency area cited in letters. Further, 56 close-out letters were sent to firms in 2013, down slightly from 2013.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.